Marseille, January 25th 2010 ‐ IPSOGEN (Alternext ‐ FR0010626028 ‐ ALIPS), a cancer ‘profiler’ that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, announces the signature of an option agreement for the worldwide and exclusive license on genomic abnormalities in the TET2 gene . The scientific corpus supporting these TET2 patent rights has been developed by a consortium of 7 public institutions led by IGR&D, the technology transfer affiliate of Institut Gustave Roussy (IGR). The identification of genomic abnormalities in TET2, which serves as a tumor‐suppressor gene, represents a breakthrough in the understanding of the origin of myeloid disorders. These abnormalities could potentially serve as a biomarker to provide clinically useful information regarding classification and prognosis of these disorders, and predisposition to develop leukemia......About IPSOGEN
Ipsogen, Cancer Profiler, develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists’ decisions along their complex therapeutic path. With more than 70 references already used routinely worldwide for the diagnosis, prognosis and follow‐up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. As for leukemia, Ipsogen’s goal is to provide diagnostic information that was not available until now. Ipsogen is also a partner of choice for pharmaceutical companies committed to the development of “companion diagnostic tests”. Strengthened by its first‐rate scientific, clinical and technological partnerships, in addition to its highly skilled multidisciplinary team in France and the USA, Ipsogen is striving to become the leader in molecular profiling of cancers. It continues its efforts to identify, develop and commercialize diagnostic tests that will become standard references and will have a significant impact on patients, medical professionals and society. Ipsogen employed 60 people as of June 30, 2009. Its headquarters are located in Marseille, France. The company also has a subsidiary, Ipsogen Inc., in New Haven, CT, USA... [PDF] IPSOGEN's Press Release -
